Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?

Cappelli S, Bellando-Randone S, Guiducci S, Matucci-Cerinic M.

Rheumatology (Oxford). 2014 Jun;53(6):975-87. Review.

2.

Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.

Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G.

Semin Arthritis Rheum. 2015 Feb;44(4):437-44. doi: 10.1016/j.semarthrit.2014.09.003. Epub 2014 Sep 8.

PMID:
25282395
3.

Interstitial lung disease in systemic sclerosis.

Bussone G, Mouthon L.

Autoimmun Rev. 2011 Mar;10(5):248-55. doi: 10.1016/j.autrev.2010.09.012. Epub 2010 Sep 21. Review.

PMID:
20863911
4.

[Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].

Sicińska J, Rudnicka L.

Pol Merkur Lekarski. 2008 Aug;25(146):192-5. Review. Polish.

PMID:
18942346
5.

Disease-modifying treatment in systemic sclerosis: current status.

Quillinan NP, Denton CP.

Curr Opin Rheumatol. 2009 Nov;21(6):636-41. doi: 10.1097/BOR.0b013e3283310d57. Review.

PMID:
19726995
6.

The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.

Baskin E, Ozen S, Cakar N, Bayrakci US, Demirkaya E, Bakkaloglu A.

Pediatr Nephrol. 2010 Jan;25(1):111-7. doi: 10.1007/s00467-009-1291-x. Epub 2009 Sep 1.

PMID:
19727839
7.

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.

Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H.

Nephrol Dial Transplant. 2007 Jul;22(7):1933-42. Epub 2007 Apr 3. Review.

8.

Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.

Lee YH, Woo JH, Choi SJ, Ji JD, Song GG.

Lupus. 2010 May;19(6):703-10. doi: 10.1177/0961203309357763. Epub 2010 Jan 11. Review.

PMID:
20064907
9.

Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.

Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.

Int J Rheum Dis. 2014 Nov;17(8):923-8. doi: 10.1111/1756-185X.12399. Epub 2014 May 26.

PMID:
24864029
10.
11.

Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, Jayne DR; European Vasculitis Study Group.

Arthritis Rheum. 2012 Oct;64(10):3472-7. doi: 10.1002/art.34547.

12.

Oral cyclophosphamide for active scleroderma lung disease: a decision analysis.

Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH.

Med Decis Making. 2008 Nov-Dec;28(6):926-37. doi: 10.1177/0272989X08317015. Epub 2008 Apr 28.

PMID:
18443209
13.

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR.

Arthritis Rheum. 2005 Aug;52(8):2461-9.

14.

Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease.

Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI.

Clin Rheumatol. 2010 Oct;29(10):1167-8. doi: 10.1007/s10067-010-1498-z. Epub 2010 Jun 10.

PMID:
20532938
15.

[Auto-immune hepatitis: therapeutic management].

Pariente A.

Gastroenterol Clin Biol. 2003 May;27(5 Suppl):B13-9. Review. French. No abstract available.

16.

Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?

Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H.

Am J Gastroenterol. 2001 Mar;96(3):782-7.

PMID:
11280551
17.

Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP.

Curr Rheumatol Rep. 2009 Apr;11(2):111-9. Review.

PMID:
19296883
18.

Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.

Fathi N, Furst DE, Clements PJ.

Curr Rheumatol Rep. 2007 May;9(2):144-50.

PMID:
17502045
19.

Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?

Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.

Ann N Y Acad Sci. 2007 Sep;1110:271-84.

PMID:
17911442
20.

Treatment of ANCA-associated vasculitis, where to go?

Kallenberg CG.

Clin Rev Allergy Immunol. 2012 Dec;43(3):242-8. doi: 10.1007/s12016-012-8325-z. Review.

PMID:
22669755
Items per page

Supplemental Content

Write to the Help Desk